Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents

Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents

  *Both patents cover the significant co-morbidity associated with low T and
    Type 2 diabetes
  *US patents 8,372,887 and 8,377,991 will expire in 2028 and 2031,

THE WOODLANDS, Texas, April 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc.^® (Nasdaq:RPRX) announced two patents representing potentially large
commercial indications for its drug Androxal have been issued. The two patents
deal with the metabolic consequences of low testosterone and the positive
outcomes associated with restoration of testicular function exhibited by
Androxal. The 8,377,991 patent specifically covers treatment of Type 2
diabetes, an area of high unmet medical need. The 991 issuance and patent life
should have a positive impact on Androxal's long-term commercial potential.

The 991 patent is based on Repros' original findings from the Phase 2 study
ZA-202. In study ZA-202, Repros investigated the potential of Androxal to
improve glycemic control in Type 2 diabetic men currently being treated with
oral hypoglycemic agents for their condition. That trial showed statistically
significant improvement in HbA1c and insulin, as well as HOMA-IR compared to
placebo in men < 55 years of age in the 3 month study. While the Company has
an active IND open with the Division of Endocrine and Metabolic Products at
the FDA, Repros has been focusing its efforts on the urological application of
Androxal as well as the Proellex woman's health program for uterine fibroids
and endometriosis.

Joseph S. Podolski, President and CEO of Repros commented, "The co-morbidity
of Type 2 diabetes, low T and obesity is undeniable. The fact that several
hormone replacement therapies have failed to show an impact on glycemic
control, underscores the potential of Androxal. This restoration of organ
function is a unique feature of Androxal compared to the approved hormone
replacement therapies." He further noted, "Today the Endocrine Society
recommends that physicians assess testosterone levels in men suspected to be
Type 2 diabetic or pre-diabetic. Androxal offers a rational approach to treat
the hypogonadal diabetic male. Endocrinologists represent a special population
of readily reached physicians that may be the first adopters of Androxal in
the treatment of hypogonadism."

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including the ability to raise additional needed capital on a
timely basis in order for it to continue to fund development of its Androxal^®
and Proellex^® programs, have success in the clinical development of its
technologies, the reliability of interim results to predict final study
outcomes, and such other risks which are identified in the Company's most
recent Annual Report on Form 10-K and in any subsequent quarterly reports on
Form 10-Q. These documents are available on request from Repros Therapeutics
or at Repros disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

For more information, please visit the Company's website at

CONTACT: Repros Therapeutics Inc.
         Joseph Podolski (281) 719-3447
         President and Chief Executive Officer
         Investor Relations: Thomas Hoffmann
         The Trout Group
         (646) 378-2931

company logo
Press spacebar to pause and continue. Press esc to stop.